share_log

Tivic Health to Report Q2 2024 Financial Results and Corporate Update on August 14th Via Conference Call and Webcast

Tivic Health to Report Q2 2024 Financial Results and Corporate Update on August 14th Via Conference Call and Webcast

Tivic 健康將於8月14日通過電話會議和網絡廣播發布2024年Q2業績和公司更新。
Tivic Health Systems ·  08/01 00:00

SAN FRANCISCO – (Business Wire) – August 6, 2024 Tivic Health Systems, Inc. ("Tivic Health", Nasdaq: TIVC), a health tech company that develops and commercializes bioelectronic medicine, today announced that it will report its Q2 2024 financial results and a corporate update via pre-recorded conference call and webcast on Wednesday, August 14 at 1:30 PM PT / 4:30 PM ET. Current shareholders, interested individuals and future investors are encouraged to join the webcast to hear the company executives provide a corporate update that will highlight the importance of Tivic's vagus nerve research program and its market potential. The company invites questions to be submitted to ir@tivichealth.com by August 11, 2024.

舊金山-(商業線)2024年8月6日-Tivic Health Systems,Inc.(「Tivic Health」,納斯達克:TIVC)是一家開發和商業化生物電療技術的醫療科技公司,今日宣佈將於美國時間8月14日星期三下午1:30點/4:30 pm Et通過預錄音會議通話和網絡直播公佈其2024年Q2財務業績和企業更新。鼓勵現有股東、有興趣的個人和未來投資者參加網絡直播以聽取公司高管提供企業更新,重點突出Tivic的迷走神經研究項目及其市場潛力。公司邀請通過ir@tivichealth.com提交問題截止日期爲2024年8月11日。

Teleconference Details:

電話會議詳細信息:

Toll Free: 888-506-0062
International: 973-528-0011
Participant Access Code: 316159

免費電話:888-506-0062
國際電話:973-528-0011
參與者接入代碼:316159

Webcast Link

網絡直播鏈接

About Tivic Health

關於Tivic Health

Tivic Health is a commercial health tech company advancing the field of bioelectronic medicine. Tivic Health's technology platforms leverage stimulation of the trigeminal, sympathetic, and vagus nerve structures. Tivic Health's non-invasive and targeted approach to the treatment of inflammatory chronic health conditions gives consumers and providers drug-free therapeutic solutions with high safety profiles, low risk, and broad applications. Tivic Health's first commercial product ClearUP is an FDA approved, award-winning, handheld bioelectronic sinus device. ClearUP is clinically proven, doctor-recommended, and is available through online retailers and commercial distributors. For more information visit @TivicHealth

Tivic Health是一家商業化健康科技公司,推進生物電醫學領域。 Tivic Health的技術平台利用三叉神經,交感神經和迷走神經結構的刺激。 Tivic Health針對慢性炎症性健康狀況的非侵入式和有針對性的治療方法爲消費者和提供者提供了無需藥物的治療解決方案,具有高安全性、低風險和廣泛應用的特點。 Tivic Health的第一個商業產品ClearUP是一種FDA批准、獲獎的手持生物電氣劍突設備。 ClearUP經過臨床驗證,得到醫生的推薦,可通過在線零售商和商業分銷商獲得。欲了解更多信息,請訪問@TivicHealth

Forward-Looking Statements

前瞻性聲明

This press release may contain "forward-looking statements" that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as "anticipate," "believe," "contemplate," "could," "estimate," "expect," "intend," "seek," "may," "might," "plan," "potential," "predict," "project," "target," "aim," "should," "will" "would," or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on Tivic Health Systems, Inc.'s current expectations and are subject to inherent uncertainties, risks, and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors. Accordingly, you are cautioned not to place undue reliance on such forward-looking statements. For a discussion of risks and uncertainties relevant to the company, and other important factors, see Tivic Health's filings with the SEC, including, its Annual Report on Form 10-K for the year ended December 31, 2023, filed with the SEC on March 29, 2024, under the heading "Risk Factors"; as well as the company's subsequent filings with the SEC. Forward-looking statements contained in this press release are made as of this date, and Tivic Health Systems, Inc. undertakes no duty to update such information except as required by applicable law.

本新聞稿可能包含「前瞻性聲明」,受到重大風險和不確定性的影響。本新聞稿中除了歷史事實之外的所有陳述都是前瞻性陳述。本新聞稿中包含的前瞻性陳述可以通過使用諸如「預測」、「相信」、「思考」、「可能」、估計”、「期望」、「意圖」、「尋找」、「可能」、「計劃」、「潛在的」、「預測」、「項目」、「目標」、「目的」、「應該」、「將」、「會」等詞語或其他類似的表達式來識別,雖然不是所有的前瞻性陳述都包含這些詞。前瞻性陳述基於Tivic Health Systems, Inc.的當前預期,並且存在難以預測的固有不確定性、風險和假設。此外,某些前瞻性陳述是基於對未來事件的假設,這些假設可能不會被證明準確。由於各種因素的影響,實際結果可能會與任何前瞻性陳述中所包含的結果有所不同。因此,您應謹慎使用這些先前的陳述。有關涉及公司的風險和不確定性以及其他重要因素的討論,請參見Tivic Health向證券交易委員會提交的文件,包括於2024年3月29日提交的截至2023年12月31日結束的年度報告10-k,其中根據「風險因素」的標題;以及公司隨後向證券交易委員會提交的文件。在本新聞稿中包含的前瞻性聲明是截至本日期,Tivic Health Systems, Inc.除根據適用法律規定外,不承擔更新此類信息的義務。

Media Contact:

媒體聯繫人:

Morgan Luke

Morgan Luke

Morgan.Luke@tivichealth.com

Morgan.Luke@tivichealth.com

Investor Contact:

投資者聯繫人:

Hanover International, Inc.

Hanover International, Inc.

ir@tivichealth.com

ir@tivichealth.com

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論